OTP E 44028 BY

PTO/SB/08a (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute Panerwork Red Con Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/014,724

Filing Date November 7, 2001

First Named Inventor Michael N. Gould

Art Unit 1618

Examiner Name Dameron L. Jones

(Use as many sheets as necessary)

Sheet 1 of 3 Attorney Docket Number 960296.97711

Examiner	Cite	Document Number	U. S. PATENT I Publication Date		Name of Patentee or		Pages, Columns, Lines, Where		
Initials*	No.¹	Number-Kind Code <sup>2 (# known)</sup>	MM-DD-YY	YY	Y Applica	ant of Cited Document		Relevant Passages or Relevant Figures Appear	
		US-				•			
		US-							
		US-							
		US-	<del></del>		·			<del>/</del> .	
		US-							
		US-							
		US-							
<del></del>		US-							
		US-	<del></del>						
		US-				<u></u>			
		US-							
		US-			<del>,</del>				
-		US-							
<del></del>		US-							
·		US-							
· · · · · · · · · · · · · · · · · · ·		US-							
		US-							
		US-							
			FOREIGN P	ATENT	DOCI	MENTS			
			TOILLION	A16-141	0000		T		Т
Examiner nitials*	Cite No. <sup>1</sup>	Egreign Patent Docur		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	r ment	Pages, Columns, Lines, Where Relevant Passages	١,
	-	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# /	ber 4 Kind Code <sup>5</sup> (# known)		,,,		or Relevant Figures Appear		╄
				• • • • • • • • • • • • • • • • • • • •		> 0,007 400 10 100 100 100 100 100 100 100 100			Ļ
		1	i			•			L
			***************************************		• •••••••	h	•	0 <del>0 0 1</del> 1 1 1 1 1 <del>1 1 1 1 1 1 1 1 1 1 1 1 1</del>	
,/			**************	• • • • • • • • • • • • • • • • • • • •		> + 4 = 1 = 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1			十
	1	<u> </u>		_		<u></u>			i.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiallty is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b (07-05)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO				Complete if Known		
					Application Number	10/014,724	
INFO	RMATION	I DISC	LC	SURE	Filing Date	November 7, 2001	
STATEMENT BY APPLICANT					First Named Inventor	Michael N. Gould	
					Art Unit	1618	
	(Use as many she	eets as nece	ssary	9	Examiner Name	Dameron L. Jones	
Sheet	2	•	of	3	Attorney Docket Number	960296.97711	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
T	1	Broitman SA, et al., "Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic 'metastases' in vivo," Adv. Exp. Med. Biol. 401:111-130, 1996.	
-		Chen Y and Hu D, "Effects of POH in combination with STI571 on the proliferation and apoptosis of K562 cells," J. Huazhon Univ. Sci. Technolog. Med. Sci. 24(1):47, 2004	
		Hyer ML, et al., "Synthetic triterpenoids cooperates with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells," Cancer Res.	
		Keane MM, et al., "Chemotherapy augments TRAIL-induced apoptosis in breast cell lines," Cancer Res. 59(3):734-741, 1999.	
	100000000000000000000000000000000000000	Mo H and Elson CE, "Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention," pp. 567-585, 2004	*************
		Rajesh D, et al., "Perillyl alcohol as a radio-/chemosensitizer in malignant glioma," J. Biol. Chem. 278(38):35968-35978, 2003.	
	•	Shi B, et al., "The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo," Cancer Chemother.  Pharmacol. 46:387-393. 2000.	
		Vigushin DM, et al., "Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee," Cancer Chemother, Pharmacol. 42(2:111-117, 1998.	<b>~ 00 00 00 00 00</b>
V		Yu D, "Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers," 28(Suppl. 16):12-17, 2001	*********
D		Zhang S, et al., "Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms," Curr. Med. Chem. Anti-Canc. Agents 5(3):239, 2005.	

Examiner Signature	Z	Jan	Date Considered	1/6	186

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OLD E 4002 M

PTO/SB/08b (07-05)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwood Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known Application Number 10/014,724 INFORMATION DISCLOSURE Filing Date November 7, 2001 STATEMENT BY APPLICANT First Named Inventor Michael N. Gould Art Unit 1618 Examiner Name (Use as many sheets as necessary) Dameron L. Jones Attorney Docket Number Sheet 3 960296.97711 3

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
0		International Agency for Research on Cancer IARC) - Summaries & Evaluations, Lumber and Sawmill Industries (Including Logging) (Group 3) Suppl. 7:383, 1987.			
	•				
		·			
. 4. 2. 00 10 144 00 100 00 00 00 00 00	***************************************				
4 = 18 98 74 80 394 9 = 1 = 1 = 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4	••••••	**************************************			
* 9					
		·			
1 0 7 1 7 2 2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7		·	•		

Examiner Signature	TOM	Date Considered
Oignature		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.